<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2605">
  <stage>Registered</stage>
  <submitdate>4/12/2009</submitdate>
  <approvaldate>4/12/2009</approvaldate>
  <nctid>NCT01028963</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CL004_140</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - pioglitazone
Treatment: drugs - CCX140-B
Treatment: drugs - CCX140-B

Placebo Comparator: Placebo - 

Active Comparator: Active control - 

Experimental: Active Study Medication (Group C) - CCX140-B

Experimental: Active Study Medication (Group D) - CCX140-B


Treatment: drugs: Placebo
Placebo capsules once daily

Treatment: drugs: pioglitazone
pioglitazone 30 mg tablet once daily

Treatment: drugs: CCX140-B
CCX140-B capsules once daily (Group C)

Treatment: drugs: CCX140-B
CCX140-B capsules once daily (Group D)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Subject incidence of adverse events</outcome>
      <timepoint>28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effect on fasting plasma glucose concentration</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Diagnosed type 2 diabetes mellitus

          -  Must have a body mass index =25 and &lt;45 kg/m2, but if body mass index is =25 and &lt;28
             kg/m2, then waist circumference must be &gt;94 cm for men and &gt;80 cm for women

          -  Must be on a stable dose of metformin for at least 8 weeks prior to randomization

          -  Hemoglobin A1c (HbA1c) of 6.5 to 10.0% inclusive and fasting plasma glucose 135 to 270
             mg/dL inclusive at Screening

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Type 1 diabetes mellitus or history of diabetic ketoacidosis

          -  Received insulin treatment within 12 weeks of randomization

          -  Received chronic (more than 7 days) systemic glucocorticoid treatment within 12 weeks
             of randomization

          -  Received sulfonylurea, thiazolidinedione, exenatide, or any other glucose lowering
             treatment (other than metformin) within 8 weeks of randomization

          -  Symptomatic congestive heart failure requiring prescription medication, clinically
             evident peripheral edema, poorly-controlled hypertension (systolic blood pressure &gt;160
             or diastolic blood pressure &gt;100), history of unstable angina, myocardial infarction
             or stroke within 6 months of randomization, or chronic renal failure

          -  History or presence of drug-induced myopathy, drug-induced creatine kinase elevation,
             or leukopenia (WBC count &lt;3.5 x 10(9)/L)

          -  History or presence of any form of cancer within the 5 years prior to randomization,
             with the exception of excised basal cell or squamous cell carcinoma of the skin, or
             cervical carcinoma in situ or breast carcinoma in situ that has been excised or
             resected completely and is without evidence of local recurrence or metastasis

          -  Fasting serum triglyceride &gt;400 mg/dL</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>159</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital> - Auchenflower</hospital>
    <hospital> - Kippa-Ring</hospital>
    <postcode> - Auchenflower</postcode>
    <postcode> - Kippa-Ring</postcode>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Beroun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hlucin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Neratovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Novy Jicin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Pardubice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prelouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Slany</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Uhersky Brod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Unicov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Usti nad Labem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Basenheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cologne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nuremberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Saarlouis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Balatonfuered</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Satoraljaujhely</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szikszo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ChemoCentryx</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and potential effectiveness of CCX140-B
      in subjects with Type 2 diabetes mellitus.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01028963</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pirow Bekker, MD, PhD</name>
      <address>ChemoCentryx, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>